Recently, the Ministry of Industry and Information Technology announced the list of National Technology Innovation Demonstration Enterprises for 2023 and the review and evaluation results of National Technology Innovation Demonstration Enterprises. A total of 68 enterprises have been newly recognized as the National Technology Innovation Demonstration Enterprises in 2023, while 248 enterprises including Kanion Pharmaceutical have successfully passed the review. Since its initial recognition as a National Technology Innovation Demonstration Enterprise in 2014, Kanion Pharmaceutical has successfully passed the review conducted by the Ministry of Industry and Information Technology three consecutive times, in 2017, 2020, and 2023.
It is understood that the National Technology Innovation Demonstration Enterprises are subject to dynamic management, with review and re-evaluation conducted every three years. Qualified demonstration enterprises are confirmed, while unqualified ones are stripped of their titles. The assessment of National Technology Innovation Demonstration Enterprises establishes 21 key indicators from three dimensions: innovation mechanisms, technology and talent, as well as output and benefits, to comprehensively and systematically evaluate the technological innovation ability of enterprises.
Jiangsu Kanion Pharmaceutical Co., Ltd. is a large-scale traditional Chinese medicine enterprise that integrates the cultivation of Chinese medicinal herbs, R&D, production, and trade of traditional Chinese medicine. It has become one of the leading enterprises in Chinese medicine industry. The company has been successively recognized as a National High-tech Enterprise, a National Innovative Pilot Enterprise, a National Technological Innovation Demonstration Enterprise, and a National Intellectual Property Demonstration Enterprise. For many years, it has ranked first in China's traditional Chinese medicine R&D strength ranking list. It is also one of the enterprises in China's traditional Chinese medicine industry with the largest number of new drug certificates, the most invention patents, and the most profound promotion of the internationalization of traditional Chinese medicine.
During the evaluation period, the company further strengthened the research and development of innovative drugs, obtaining 4 approvals for the registration of new traditional Chinese medicines, 12 clinical licenses, 3 approvals for the registration of chemical generic drugs, and 6 approval documents for the consistency evaluation of chemical generic drugs. Among them, Bone Acesodyne Gel is the first traditional Chinese medicine gel to be marketed in the past decade, Yinqiao Heat-clearing Tablet is the first class 1.1 innovative traditional Chinese medicine approved since the implementation of the New Drug Registration Management Measures in 2020, Cold-dispelling Dehumidification Granule is the first new anti-epidemic drug approved for the treatment of COVID-19 infection after the "three methods and three drugs", and Linggui Zhugan Granule is the first Class 3.1 new traditional Chinese medicine approved for marketing since the implementation of the New Drug Registration Management Measures in 2020.
During the evaluation period, the company applied for 82 patents for its innovation achievements and was granted 130 patents. It also published 191 academic papers (including 76 SCI papers). For the first time in the industry, the company systematically formulated and released 19 technical standards for intelligent manufacturing of traditional Chinese medicine (1 group standard and 18 enterprise standards), establishing a mature and complete intelligent manufacturing technology system. The company won 1 second prize of National Science and Technology Progress Award and 1 first prize of Science and Technology Progress Award of China Association of traditional Chinese Medicine. The company's R&D team was awarded the 20th "National Youth Civilized Unit" collective, and the innovative traditional Chinese medicine R&D team won the honorary title of "the 6th National Professional Technical Talents Advanced Collective" in 2021. The company was also ranked first in the list of traditional Chinese medicine R&D strength.
As a national technology innovation demonstration enterprise, Kanion Pharmaceutical will effectively play a exemplary and leading role, constantly improve institutional construction, increase investment in technological innovation, strengthen key core technology research and development, continuously enhance independent innovation capabilities, and make positive contributions to the innovative development of traditional Chinese medicines, demonstrating and leading the high-quality development of China's traditional Chinese medicine industry.
